Author:
Yu Xue,Wang Yan,Lai Jianming,Song Ting,Duan Jianping
Funder
Qingdao Science and Technology Benefit People Demonstration and Guidance Project
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Kessoku T, Imajo K, Kobayashi T et al (2020) Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. The lancet Gastroenterology & hepatology 5(11):996–1007. https://doi.org/10.1016/s2468-1253(20)30216-8
2. Cai J, Zhang XJ, Ji YX et al (2020) Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res 126(5):679–704. https://doi.org/10.1161/CIRCRESAHA.119.316337
3. Hariri M, Gholami A, Mirhafez SR et al (2020) A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled, clinical trial. Complement Ther Med. https://doi.org/10.1016/j.ctim.2020.102447
4. Yao J, Meng M, Yang S et al (2018) Effect of aerobic and resistance exercise on liver enzyme and blood lipids in Chinese patients with nonalcoholic fatty liver disease: a randomized controlled trial. Int J Clin Exp Med 11(5):4867–4874
5. Wong VW, Wong GL, Chan RS et al (2018) Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol 69(6):1349–1356. https://doi.org/10.1016/j.jhep.2018.08.011
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献